Zentalis Pharmaceuticals Inc
Ouvert
3.54 -9.23
Résumé
Variation du prix de l'action
24h
Min
3.51
Max
3.9699999999999998
Revenu | -136K -35M |
|---|---|
BPA | -0.503 |
Employés | 106 |
EBITDA | -619K -38M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +86.67% upside |
Prochains Résultats | 4 août 2026 |
|---|
Capitalisation Boursière | -34M 261M |
|---|---|
Ouverture précédente | 12.77 |
Clôture précédente | 3.54 |
Zentalis Pharmaceuticals Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.